ALDX — Aldeyra Therapeutics Share Price
0.000.00%
Last trade - 00:00- $168.31m
- $82.19m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.37 | ||
| Price to Tang. Book | 2.37 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.9% | ||
| Return on Equity | -58.54% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 58.21 | 48.91 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
Directors
- Richard Douglas NEC (68)
- Todd Brady PRE (49)
- Joshua Reed CFO (48)
- Stephen Machatha OTH (44)
- Ben Bronstein IND (71)
- Martin Joyce IND (67)
- Nancy Miller-rich IND (62)
- Gary Phillips IND (55)
- Neal Walker IND (51)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 13th, 2004
- Public Since
- May 2nd, 2014
- No. of Shareholders
- 18
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 59,895,588
- Address
- 131 HARTWELL AVENUE, SUITE 320, LEXINGTON, 02421
- Web
- https://www.aldeyra.com/
- Phone
- +1 7817614904
- Contact
- David Burke
- Auditors
- BDO USA, LLP
Upcoming Events for ALDX
Aldeyra Therapeutics Inc Annual Shareholders Meeting
Aldeyra Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Aldeyra Therapeutics Inc Earnings Release
Similar to ALDX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Aldeyra Therapeutics share price?
As of Today at 19:10 UTC, shares in Aldeyra Therapeutics are trading at $2.81. This share price information is delayed by 15 minutes.
How has the Aldeyra Therapeutics share price performed this year?
Shares in Aldeyra Therapeutics last closed at $2.81 and the price had moved by -33.25% over the past 365 days. In terms of relative price strength the Aldeyra Therapeutics share price has underperformed the S&P500 Index by -39.81% over the past year.
What are the analyst and broker recommendations for Aldeyra Therapeutics?
The overall consensus recommendation for Aldeyra Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aldeyra Therapeutics dividend yield?
Aldeyra Therapeutics does not currently pay a dividend.
Does Aldeyra Therapeutics pay a dividend?
Aldeyra Therapeutics does not currently pay a dividend.
When does Aldeyra Therapeutics next pay dividends?
Aldeyra Therapeutics does not currently pay a dividend.
How do I buy Aldeyra Therapeutics shares?
To buy shares in Aldeyra Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aldeyra Therapeutics?
As of the previous close price of $2.81, shares in Aldeyra Therapeutics had a market capitalisation of $168.31m.
Where are Aldeyra Therapeutics shares listed?
Here are the trading details for Aldeyra Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ALDX
What kind of share is Aldeyra Therapeutics?
Based on an overall assessment of its quality, value and momentum Aldeyra Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aldeyra Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Aldeyra Therapeutics is $8.29. That is 195.02% above the last closing price of $2.81.
Analysts covering Aldeyra Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.40 for the next financial year.
Find out moreWhat is the trend in the Aldeyra Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aldeyra Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -47.33%.
As of the last closing price of $2.81, shares in Aldeyra Therapeutics were trading -44.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aldeyra Therapeutics PE Ratio?
The Aldeyra Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aldeyra Therapeutics?
Aldeyra Therapeutics' management team is headed by:
- Richard Douglas - NEC
- Todd Brady - PRE
- Joshua Reed - CFO
- Stephen Machatha - OTH
- Ben Bronstein - IND
- Martin Joyce - IND
- Nancy Miller-rich - IND
- Gary Phillips - IND
- Neal Walker - IND